Mankind Pharma Ltd News

Mankind Pharma shares gain 3% on acquiring Rivotril brand rights from Roche

The acquisition is expected to strengthen Mankind Pharma's presence in the central nervous system (CNS) segment and complement its existing neuro portfolio

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Suzlon, Ola Electric, Bata, RPower, Wipro hit 52-week lows in firm market

Wipro, Cyient, Hexaware Technologies, KPIT Technologies and L&T Technology Services from the IT sector and Info Edge (India) and C.E. Info Systems from the IT-related sector hit 52-week lows on Monday

JM Financial flags growth concerns in Mankind Pharma; initiates with Reduce

JM Financial raised concerns around Mankind Pharma's recent BSV acquisition, which was executed at a high valuation and is expected to dilute return on capital

Mankind Pharma shares drop 4% even as Q3 profit rises; check outlook

Mankind Pharma recorded profit after tax (PAT) of ₹414 crore, up from ₹378 crore in the same quarter last year. Its revenue from operations also grew 11.5 per cent

Stocks to Watch: Bajaj Finance, Nazara Tech, Mankind Pharma, NBCC, Pidilite

Stocks to Watch today: Bajaj Finance, Nazara Technologies, Aditya Birla Capital, Mankind Pharma, Restaurant Brands Asia and NBCC are among the stocks to watch today, February 04, 2026

Mankind Pharma Q3 PAT up 9.5%, revenue rises 11.5% on chronic drugs sales

Mankind Pharma posted a 9.5 per cent rise in Q3FY26 net profit and 11.5 per cent growth in revenue, driven by strong domestic demand for chronic therapies

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Mankind Pharma inks licencing pact with Actimed for cachexia treatment

Mankind Pharma has entered a licensing agreement with Actimed Therapeutics to develop and commercialise cachexia treatment products across India and neighbouring South Asian markets

Stocks to Watch today, Nov 7: Bharti Airtel, LIC, Lupin, Bajaj Housing

Stocks to Watch today, November 7, 2025: From Bharti Airtel, LIC, Bajaj Housing Finance, Lupin, here is a list of stocks that will be in focus today

Mankind Pharma Q2 PAT drops 21% on high finance costs; revenue up 20%

Mankind Pharma's Q2 FY26 profit fell to Rs 520 crore on higher finance and input costs, even as strong domestic and export growth lifted revenue by over 20%.